Johnson & Johnson announced that its innovative treatment drug Taluclotide (Te Litu Dantang Injection) has been officially approved by the National Medical Products Administration (NMPA). The drug is used as a monotherapy for relapsed or refractory multiple myeloma (RRMM) in adult patients who have received at least three lines of treatment (including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody). Taluclotide is the first bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3 that has been approved for the treatment of RRMM and has already been approved for marketing in countries or regions such as the United States and Europe.
强生宣布首个治疗多发性骨髓瘤的BCMA×CD3双抗泰立珂在华获批
Johnson & Johnson announced that the BCMA×CD3 bispecific antibody Taluclotide for treating multiple myeloma has been approved in China.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.